{
    "organizations": [],
    "uuid": "7d326183817e7aafa93bdc728237192960dbfc7d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-theravance-expects-to-report-data/brief-theravance-expects-to-report-data-from-phase-2a-study-in-noh-patients-by-july-end-idUSFWN1SO0P7",
    "ord_in_thread": 0,
    "title": "BRIEF-Theravance Expects To Report Data From Phase 2A Study In nOH Patients By July End",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 17 (Reuters) - Theravance Biopharma Inc:\n* THERAVANCE BIOPHARMA TO HOST KEY OPINION LEADER EVENT FOCUSED ON THE UNMET MEDICAL NEED IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION\n* THERAVANCE BIOPHARMA INC - COMPANY EXPECTS TO REPORT DATA FROM AN EXPLORATORY PHASE 2A STUDY IN NOH PATIENTS BY END OF JULY 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-17T20:43:00.000+03:00",
    "crawled": "2018-05-18T19:32:46.012+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "theravance",
        "biopharma",
        "inc",
        "theravance",
        "biopharma",
        "host",
        "key",
        "opinion",
        "leader",
        "event",
        "focused",
        "unmet",
        "medical",
        "need",
        "treatment",
        "neurogenic",
        "orthostatic",
        "hypotension",
        "theravance",
        "biopharma",
        "inc",
        "company",
        "expects",
        "report",
        "data",
        "exploratory",
        "phase",
        "2a",
        "study",
        "noh",
        "patient",
        "end",
        "july",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}